Comment from Sandoz Inc.

Summary: Sandoz Inc. opposes the inclusion of Copaxone® (glatiramer acetate injection) on the list of products to be deemed biological products under the BPCI Act. The company argues that Copaxone® does not meet the "protein" size or "specific defined sequence" requirements because it is a mixture of random polypeptides with an undefined structure.